FLUO.ST is trading at 7.2% up now at SEK 41.60 after the company reaffirmed its 2026 financial outlook and updated timelines for its lead cancer imaging drug FG001. Investors appear to be responding positively to confirmation that overall progress remains on track, even though part two of the FG001 head and neck cancer trial has been pushed to Q4 2026 with topline results now expected in 2027.